6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
20m ago	NOV Reports First Quarter 2026 Earnings
20m ago	Irenic Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering
20m ago	Turning Point Brands to Host Q1 2026 Conference Call
20m ago	Performance Shipping Inc. Announces Filing of 2025 Annual Report on Form 20-F
20m ago	Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

About

Mink Therapeutics Inc (NASDAQ:INKT) — investor relations, events, news, and company updates on 6ix.

Latest News

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Financials

Revenue

$0

Market Cap

$56.96 M

EPS

-2.93

Community Chat

Ask AI